Genenta Science SpA ADR Dossier - Source-backed chat

Genenta Science SpA ADR

GNTANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.84

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.80Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $38.8M

Shares Outstanding 48.2M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Genenta Science S.p.A. is undergoing a pivotal strategic transformation from a pure-play clinical-stage biotechnology company into a diversified strategic holding platform named Saentra Forge S.p.A. This new model focuses on acquiring privately held Italian businesses operating in high-barrier, national-security regulated sectors (defense, aerospace, cybersecurity) protected by Italy's Golden Power framework, while simultaneously seeking to partner its promising Temferon cell-based gene therapy platform. Backed by a solid cash position of approximately 28.1 million (as of Dec 31, 2025) and a 20 million mandatory convertible bond from ENEA Tech and Biomedical, the company is uniquely positioned to consolidate profitable small-to-medium defense enterprises (such as Sòphia High Tech and ATC) while retaining significant upside from its oncology pipeline.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.2820%

Integration challenges or regulatory delays under Italy's Golden Power framework slow down the acquisition pipeline. The company fails to secure a partner for Temferon, leading to continued high R&D cash burn and potential dilution through its ATM or shelf facilities, while the biotech platform's value remains locked.

Base CaseCentral scenario

$4.5550%

The company successfully rebrands to Saentra Forge and completes the initial acquisitions of Sòphia High Tech and ATC, establishing a stable revenue-generating defense and aerospace segment. The Temferon GBM trial continues to show positive survival data, keeping the door open for a mid-stage clinical partnership within 12-18 months.

Bull CaseUpside scenario

$7.0030%

Rapid and successful execution of the Saentra Forge roll-up strategy, acquiring highly profitable defense and aerospace suppliers at attractive multiples. Simultaneously, Genenta secures a high-value global licensing partnership for Temferon in glioblastoma and renal cell carcinoma, providing substantial non-dilutive milestone payments and validating the platform's clinical efficacy.

Scenarios reflect our research view at the research date.

Key Investment Merits

Pivotal shift to a diversified, revenue-generating industrial consolidator model in high-barrier national security sectors.
Strong balance sheet with 28.1 million in cash/securities (Dec 31, 2025) and a 20 million convertible bond commitment.
Promising clinical data for lead candidate Temferon, showing a 44% 18-month survival rate and 29% 2-year survival rate in GBM patients.
Protection and stability offered by alignment with Italy's Golden Power regulatory framework.

Key Investment Risks

Execution and integration risks associated with transitioning from biotech to defense/aerospace consolidation.
High dependence on securing a strategic partner to fund and advance the clinical development of Temferon.
Regulatory hurdles and government approvals required for defense-sector acquisitions in Italy.
Potential equity dilution from the utilization of outstanding shelf registration and ATM programs.

Thesis Invalidation Triggers

Failure to obtain shareholder approval for the strategic transformation, name change, or reverse stock split at the June 2026 meeting.
Inability to close the definitive agreements with Sòphia High Tech or ATC.
A complete halt or negative clinical safety signal in the ongoing Temferon glioblastoma trial.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.